Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
Authors: David A. Reardon
Annick Desjardins
James J. Vredenburgh
James E. Herndon
April Coan
Sridharan Gururangan
Katherine B. Peters
Roger McLendon
Sith Sathornsumetee
Jeremy N. Rich
Eric S. Lipp
Dorothea Janney
Henry S. Friedman
Duke University
Mahidol University
Cleveland Clinic Foundation
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 1-Oct-2012
Citation: Cancer. Vol.118, No.19 (2012), 4759-4767
Abstract: BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratified patients into astrocytoma and oligodendroglioma cohorts. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 400 mg per day for patients not on enzyme-inducing antiepileptic drugs (EIAEDs) and at 500 mg twice a day if on EIAEDs. The primary endpoint was progression-free survival at 12 months (PFS-12) and secondary endpoints were safety, median progression-free survival, and radiographic response rate. RESULTS: Thirty-Two patients were enrolled into each cohort. Eleven patients (17%) had before radiotherapy and 24 (38%) had received before chemotherapy. The median PFS and PFS-12 were 11 months and 39%, respectively. Outcome did not differ between the histologic cohorts. No patient achieved a radiographic response. The most common grade 3 or greater adverse events were neutropenia (11%), thrombocytopenia (3%), and diarrhea (3%). CONCLUSIONS: Imatinib plus hydroxyurea was well tolerated among recurrent/progressive LGG patients but this regimen demonstrated negligible antitumor activity. © 2012 American Cancer Society.
ISSN: 10970142
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.